Filing Analysis
Tenax Therapeutics reported the results of its 2026 annual meeting of stockholders held on June 2, 2026. The stockholders elected the Board of Directors for one-year terms and ratified the appointment of Cherry Bekaert LLP as the independent auditor for the fiscal year ending December 31, 2026.
📋 Key Facts
- Annual Meeting held on June 2, 2026.
- Seven directors were elected to one-year terms expiring in 2027: June Almenoff, Michael Davidson, Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, and Stuart Rich.
- Cherry Bekaert LLP was ratified as the independent registered public accounting firm for 2026 with 21,304,543 votes in favor.
Tenax Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release attached as an exhibit to the 8-K filing.
📋 Key Facts
- The filing was made on May 12, 2026, reporting results for the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release is included as Exhibit 99.1.
- The filing was signed by Christopher T. Giordano, President and Chief Executive Officer.
Tenax Therapeutics has appointed Thomas R. Staab, II as Chief Financial Officer, effective May 11, 2026, replacing interim CFO Thomas A. McGauley. Mr. Staab brings extensive executive experience from BioCryst Pharmaceuticals and LENSAR, and his compensation package includes significant equity inducements.
📋 Key Facts
- Thomas R. Staab, II appointed as CFO effective May 11, 2026.
- Interim CFO Thomas A. McGauley will resign effective May 10, 2026, but will remain as principal financial officer through the filing of the Q1 2026 Form 10-Q.
- Mr. Staab's compensation includes an annual base salary of $428,000 and a 45% target bonus.
- Inducement equity awards consist of 10,000 restricted stock units (RSUs) and options to purchase 450,000 shares of common stock.
- Mr. Staab previously served as CFO of LENSAR, Inc. (NASDAQ: LNSR) and BioCryst Pharmaceuticals (NASDAQ: BCRX).
Tenax Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The disclosure was made via a press release on March 10, 2026, and filed under Item 2.02.
📋 Key Facts
- Financial results cover the fourth quarter and full year ended December 31, 2025.
- The report was filed on March 10, 2026.
- The filing includes Exhibit 99.1, which is the press release containing the detailed financial results.